Before taking this drug, tell your doctor if you have liver disease, any allergies (especially drug allergies), blood disorders (hemophilia) or diabetes.

Tell your doctor if you are pregnant before taking this medication.

It is not known whether this drug is excreted into human milk.

HIV-infected mothers are advised to avoid breast-feeding in order to protect the infant from becoming infected with HIV.

Patients taking birth control pills should use a different or additional method of birth control during treatment with nelfinavir.

Caution is advised if this drug is used in children under 2 years of age.

For information on Medic Alert(TM) call 1-800-854-1166.

In Canada call 1-800-668-1507.

Generic Name: Nelfinavir Mesylate

Viracept 250 mg Tablet - Prescription

nelfinavir

An antiviral drug that slow the growth of HIV, the virus associated with AIDS Nelfinavir belongs to a group of drugs called protease inhibitors.
It reduces the amount of HIV virus (viral load) and increases the number of CD4 cells (T cells or immune cells) in the blood.
The dose of nelfinavir is based on the child's weight (20 to 30 milligrams per kilogram of body weight).
Check with your doctor IMMEDIATELY if any of the following side effects occur: nausea, vomiting or severe abdominal pain.

http://www.cw.bc.ca/oaktree/pdf/nelfinavir.pdf
Please discuss ALL medications that you are currently taking with your doctor or pharmacist. nelfinavir, virus.

nelfinavir

Nelfinavir was approved in 1997 as an antiviral drug for people with HIV Using 250 mg capsules, this meant taking 3 capsules at a time.
Late in 1999, the FDA approved twiceThere are no absolute rules about when daily dosing of nelfinavir at 1250 mg per to start antiviral drugs.
You and your doctor should consider your T-cell dose.
In April 2003 the FDA approved count, your viral load, any symptoms a 625 mg tablet.
They are slightly different from the original virus.
Make sure that your doctor knows about ALL drugs you are taking.

http://www.thebody.com/nmai/pdfs/nelfinavir.pdf
A Project of the New Mexico AIDS Education and Training Center. nelfinavir, Mexico.

ergotamine_public_e

This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc. Contact the company for a copy of any references, attachments or enclosures.

Novartis is cautioning physicians and patients about the risk of stroke and/or gangrene when medications containing ergotamine or dihydroergotamine are taken at the same time as certain antibiotic, antiviral and antifungal drugs DORVAL, Quebec (February 18, 2003) -- Following discussions with Health Canada, Novartis Pharmaceuticals Canada Inc. has informed physicians and pharmacists, through a Dear Health Professional Letter, that prescription products containing ergotamine (er-gotah-meen) or dihydroergotamine (dye-hi-dro-er-go-tah-meen) must not be taken with drugs that can cause the amount of ergotamine in the body to rise to toxic levels. Canada, contraindications.

20779s32lbl

VIRACEPT (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
Drug combination studies with protease inhibitors (ritonavir, saquinavir or indinavir) showed variable results ranging from antagonistic to synergistic.
*Twelve patients in the BID arm and fourteen patients in the TID arm have not yet reached 48 weeks of therapy **These rates only reflect dose-limiting toxicities that were counted as the initial reason for treatment failure in the analysis (See ADVERSE REACTIONS for a description of the safety profile of these regimens).

http://www.fda.gov/cder/foi/label/2001/20779s32lbl.pdf
Co-administration of VIRACEPT and drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects. patients, Administration.

VIRACEPT

Mechanism of Action: Nelfinavir is an inhibitor of the HIV-1 protease.
have demonstrated loss of virologic response to a nelfinavir-containing regimen.
Phenytoin exposure measures are reported for total phenytoin exposure.
copies/mL, using the Roche HIV-1 Ultrasensitive assay (Study Avanti 3).
changes in CD4 cell count are summarized in Figures 1 and 2, respectively.
protease inhibitor therapy, hyperglycemia persisted in some cases.
Nelfinavir is principally metabolized by the liver.
exercised when administering this drug to patients with hepatic impairment.
Urogenital System: kidney calculus, sexual dysfunction and urine abnormality.